CD8A and neoplasm: The PACIFIC trial (dCRT followed by durvalumab for the treatment of stage III NSCLC) established a basis for consolidative immunotherapy in unresectable NSCLC.26 Some research has indicated that concurrent dCRT at different time points may result in variations in peripheral blood tumor-reactive CD8+ T-cells.